Aeterna Zentaris Publicizes European Licensing Settlement with Consilient Well being Ltd. for Commercialization of Macimorelin Nasdaq:AEZS

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), via its wholly-owned subsidiary, (“Aeterna” or the “Firm”), a specialty biopharmaceutical firm commercializing and growing therapeutics and diagnostic checks, in the present day introduced that it has entered into an unique licensing settlement (the “Settlement”) with Consilient Well being, Ltd. (“CH” or “Consilient Well being”), a privately owned pharmaceutical firm centered on commercializing medicines in Europe and Center East, for the commercialization in Europe and the UK of macimorelin, Aeterna’s orally out there ghrelin agonist, in any diagnostic utility, together with the analysis of sufferers with grownup development hormone deficiency (“AGHD”) and, topic to receipt of regulatory approval, childhood-onset development hormone deficiency (“CGHD”).

Below the phrases of the Settlement, CH will likely be chargeable for acquiring pricing and reimbursement approval within the European financial space and the UK, in addition to bearing the regulatory value for the label extension for pediatric use pending profitable end result of the upcoming security and efficacy examine, AEZS-130-P02 (“Research P02”), evaluating macimorelin for the analysis of CGHD. This pivotal Part three Research P02 is anticipated to be initiated in Q1 of 2021. Aeterna and Consilient Well being have additionally entered right into a separate business provide settlement beneath which Consilient Well being will buy macimorelin from Aeterna and Aeterna will likely be chargeable for provide and product high quality. Aeterna will proceed to keep up management of its patents overlaying macimorelin in Europe and the UK.

As agreed, Consilient Well being will make an up-front cost to Aeterna of Euro 1 million and can pay to Aeterna royalties on internet gross sales of macimorelin starting from 10% to 20% relying on the extent of internet gross sales achieved by Consilient Well being within the explicit 12 months. Aeterna will even be eligible to obtain milestone funds related to the achievement of pricing and reimbursement approvals in sure nations in Europe and in the UK, upon approval of macimorelin in CGHD, and on the attainment by Consilient Well being of different gross sales based mostly occasions.

“This license settlement represents one other important milestone for the Firm as we proceed to safe and bolster our portfolio of selling companions for macimorelin in key markets. As a synergistic companion of selection with perception and commercialization capabilities, we imagine that Consilient Well being brings noteworthy experience that’s the proper match for Aeterna. We’re grateful for his or her partnership and stay up for leveraging their expertise in driving revolutionary advertising to our worldwide distribution community for macimorelin,” commented Dr. Klaus Paulini, Chief Government Officer of Aeterna Zentaris.

Commenting on the settlement, Ahmed Al-Derzi, Consilient Well being’s CEO said, “We’re delighted to construct this partnership with Aeterna Zentaris for macimorelin. Not solely does the model additional strengthen our rising providing to endocrinology specialists and their sufferers but it surely additionally strengthens CH’s place throughout Europe. Macimorelin is an thrilling innovation within the subject of development hormone deficiency.”

Along with advancing its pediatric program, Aeterna is actively pursuing its enterprise growth actions with the aim of securing advertising companions for macimorelin for the analysis of development hormone deficiency in extra markets the place the Firm doesn’t have already got partnership agreements.

The Settlement will likely be filed on SEDAR at The foregoing description of the phrases of the Settlement doesn’t purport to be full and is certified in its entirety by reference to the Settlement.

About Consilient Well being

Consilient Well being is a pharmaceutical firm with a wealthy heritage of commercializing merchandise in areas resembling ladies’s well being, urology and endocrinology.

In all of Consilient Well being’s planning, the affected person could be very a lot on the heart. Contemplating the wants of each the healthcare skilled and the payer, in addition to these of the affected person is essential to its business success.

Established in 2005, Consilient Well being’s success has been constructed on cultivating robust partnerships with pharma corporations and on guaranteeing entry after which advertising prescription healthcare merchandise throughout Europe and the Center East.

About Macimorelin
Macimorelin, a ghrelin agonist, is an orally energetic small molecule that stimulates the secretion of development hormone from the pituitary gland. Stimulated development hormone ranges are measured in blood samples after oral administration of macimorelin for the evaluation of GHD.

In December 2017, america Meals and Drug Administration (“FDA”) granted Aeterna Zentaris advertising approval for macimorelin for use within the analysis of sufferers with grownup development hormone deficiency. Macrilen™ has been granted Orphan Drug designation by the FDA for analysis of AGHD. In January 2019, the European Fee granted advertising authorization for macimorelin to Aeterna Zentaris for analysis of development hormone deficiency in adults. In March 2017, the Pediatric Committee of the EMA agreed to the Firm’s PIP for macimorelin, a prerequisite for submitting a advertising authorization utility for any new medicinal product in Europe.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical firm commercializing and growing therapeutics and diagnostic checks. The Firm’s lead product, macimorelin, is the primary and solely U.S. FDA and European Fee accepted oral check indicated for the analysis of grownup development hormone deficiency (AGHD). Macimorelin is presently marketed in america beneath the tradename Macrilen™ via a license settlement with Novo Nordisk the place Aeterna Zentaris receives royalties on gross sales. Based on a commercialization and provide settlement, MegaPharm Ltd. will search regulatory approval after which commercialize macimorelin in Israel and the Palestinian Authority. Moreover, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will likely be marketed in Europe and the UK via a lately established license settlement with Consilient Well being Ltd and Aeterna Zentaris will obtain royalties on gross sales and different potential funds.

Aeterna Zentaris can also be leveraging the scientific success and compelling security profile of macimorelin to develop it for the analysis of childhood-onset development hormone deficiency (CGHD), an space of great unmet want.

The Firm is actively pursuing enterprise growth alternatives for the commercialization of macimorelin in Europe and the remainder of the world, along with different non-strategic belongings to monetize their worth. For extra info, please go to and join with the Firm on Twitter, LinkedIn and Fb.

Ahead-Trying Statements

This press launch incorporates forward-looking statements (as outlined by relevant securities laws) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which replicate our present expectations relating to future occasions. Ahead-looking statements embrace these regarding the Firm acquiring approval of macimorelin for CGHD, the Firm’s skill to safe advertising companions for macimorelin in different key markets, the timing of the graduation of the CGHD Research P02, and will embrace, however usually are not restricted to statements preceded by, adopted by, or that embrace the phrases “will,” “expects,” “believes,” “intends,” “would,” “may,” “could,” “anticipates,” and comparable phrases that relate to future occasions, efficiency, or our outcomes. Ahead-looking statements contain recognized and unknown dangers and uncertainties, together with these mentioned on this press launch and in our Annual Report on Type 20-F, beneath the caption “Key Info – Danger Components” filed with the related Canadian securities regulatory authorities in lieu of an annual info kind and with the U.S. Securities and Change Fee. Identified and unknown dangers and uncertainties may trigger our precise outcomes to vary materially from these in forward-looking statements. Such dangers and uncertainties embrace, amongst others, our skill to lift capital and acquire financing to proceed our presently deliberate operations, our skill to proceed to checklist our Frequent Shares on the NASDAQ, our now heavy dependence on the success of Macrilen™ (macimorelin) and associated out-licensing preparations and the continued availability of funds and sources to efficiently commercialize the product, together with our heavy reliance on the success of the License Settlement with Novo Nordisk, the worldwide instability because of the international pandemic of COVID-19, and its unknown potential impact on our deliberate operations, together with research, our skill to enter into out-licensing, growth, manufacturing, advertising and distribution agreements with different pharmaceutical corporations and hold such agreements in impact, our reliance on third events for the manufacturing and commercialization of Macrilen™ (macimorelin), potential disputes with third events, resulting in delays in or termination of the manufacturing, growth, out-licensing or commercialization of our product candidates, or leading to important litigation or arbitration, uncertainties associated to the regulatory course of, unexpected international instability, together with the instability because of the international pandemic of the novel coronavirus, our skill to effectively commercialize or out-license Macrilen™ (macimorelin), our reliance on the success of the pediatric scientific trial within the European Union (“E.U.”) and U.S. for Macrilen™ (macimorelin), the diploma of market acceptance of Macrilen™ (macimorelin), our skill to acquire essential approvals from the related regulatory authorities to allow us to make use of the specified model names for our product, our skill to efficiently negotiate pricing and reimbursement in key markets within the E.U. for Macrilen™ (macimorelin), any analysis of potential strategic options to maximise potential future development and shareholder worth could not lead to any such various being pursued, and even when pursued, could not consequence within the anticipated advantages, our skill to make the most of enterprise alternatives within the pharmaceutical trade, our skill to guard our mental property, and the potential of legal responsibility arising from shareholder lawsuits and normal modifications in financial circumstances. Traders ought to seek the advice of our quarterly and annual filings with the Canadian and U.S. securities commissions for extra info on dangers and uncertainties. Given these uncertainties and danger elements, readers are cautioned to not place undue reliance on these forward-looking statements. We disclaim any obligation to replace any such elements or to publicly announce any revisions to any of the forward-looking statements contained herein to replicate future outcomes, occasions or developments, until required to take action by a governmental authority or relevant regulation.

Investor Contact:

Jenene Thomas
JTC Workforce
T (US): +1 (833) 475-8247
E: [email protected]

Similar Articles


Most Popular

17 Kids Who Were Confused About Why Their Actions Made Their Parents Laugh So Hard

REvil ransomware is back in full attack mode and leaking data – BleepingComputer

A West Virginia city is taking a Tesla patrol car for a test drive – CNN